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1. 
WOUND CARE 
REFERENCE TO RELATED APPLICATION 
This is a continuation of U.S. application Ser. No. 12/683, 
244, filed Jan. 6, 2010, now U.S. Pat. No. 8,173,154 the entire 
disclosure of which is incorporated by reference. 
STATEMENT OF GOVERNMENT INTEREST 
This invention was made with Government support under 
Department of the Army contract W81XWH-08-1-7065. The 
Government may have certain rights in the invention. 
FIELD OF THE INVENTION 
This invention relates to biocompatible dressings for care 
of open wounds such as lacerations, diabetic ulcers, bed 
Sores, and burns. 
BACKGROUND OF THE INVENTION 
As noted in U.S. Pat. No. 7,638,484, (i) inflammation; (ii) 
fibroblast proliferation; (iii) blood vessel proliferation; (iv) 
connective tissue synthesis; (V) epithelialization; and (vi) 
wound contraction, are among the processes occurring during 
healing of open cutaneous injuries. Various factors including 
malnutrition, infection, and pharmacological agents can 
affect the healing process. 
U.S. Pat. No. 7,605,298 discloses a wound covering con 
taining Ag, Cu, and/or Zn as an antimicrobially active Sub 
stance bonded to the surface of a matrix. The covering 
includes a first layer formed by an absorbent matrix and an 
antimicrobially active Substance, the Substance being present 
chemically or physically bonded to one surface of the matrix. 
The Surface of the matrix including the Substance is coated 
with a hydrophilic polymer. The matrix contains fibers and 
can consist of a nonwoven material, of gauze, of a foam 
material, or of another soft absorbent material. A foam mate 
rial is stated to have the advantage that it can bind material 
discharging from the wound and thereby can be kept remote 
from the wound, so that it does not interfere with the healing 
process. The matrix can contain at least one fiber or beformed 
from at least one fiber. 
U.S. Pat. No. 7,517,536 discloses a wound dressing com 
prising a flexible base layer and an antimicrobial material, 
wherein the antimicrobial material comprises an activated 
carbon-carried noble metal. The activated carbon is selected 
from among an activated carbon powder, an activated carbon 
particle, and an activated carbon fiber. The noble metal is 
selected from the group consisting of silver, gold, palladium, 
platinum, copper, and zinc. 
U.S. Pat. No. 7,495,146 discloses a wound dressing 
employing silver compounds and copper compounds in par 
ticles suspended in a fluid soluble material to establish elec 
trochemical potential adjacent a healing wound. 
U.S. Pat. No. 5,977,428 discloses an absorbent dressing 
comprising a copper-containing compound or complex as a 
micronutrient and a plurality of absorbent dried hydrogel 
particles sealed within a porous container, wherein the porous 
container is non-adherent to the wound. The absorbent hydro 
gel particles, after absorbing the exudate, remain sealed 
within the porous container. 
U.S. Pat. No. 7,166,549 discloses grinding silicate glasses 
ribbons into antimicrobial, anti-inflammatory, wound-heal 
ing glass powders which may be added as a foodstuff Supple 













medicinal products, plastics and polymers, sanitary paper, 
dyes, and lacquers as well as plaster and purification means. 
Patent application publication WO 80/02378 discloses a 
carrier manufactured from an absorbable plastic, ethylene/ 
vinyl acetate, collagen, or albumin material for promoting 
vascularization and endothelial activity in mammals. The 
carrier is in the form of a tube, sheet, thread, or net, and can, 
for example, be laid over skin ulcers. 
There is a continuing need for new approaches for accel 
erating the processes associated with healing open wounds 
such as but not limited to lacerations, diabetic ulcers, bed 
Sores, and burns. 
SUMMARY OF THE INVENTION 
Briefly, therefore, the invention is directed to flexible dress 
ing for wound care management comprising a three-dimen 
sional compressible body of loose glass-based fibers; wherein 
the fibers comprise one or more glass-formers selected from 
the group consisting of POs, SiO, and BO; at least about 
25 wt % of the fibers have a diameter between about 200 nm. 
and about 4000 nm, and a length:width aspect ratio of at least 
about 10. 
The invention is also directed to rigid dressing for wound 
care management comprising a three-dimensional body of 
bonded glass-based fibers; wherein the fibers comprise one or 
more glass-formers selected from the group consisting of 
POs, SiO, and BO; and at least about 25 wt % of the fibers 
have a diameter between about 200 nm and about 4000 nm, 
and a length:width aspect ratio of at least about 10. 
In another aspect, the invention is directed to a dressing for 
wound care management comprising a three-dimensional 
compressible body of glass-based biocompatible material 
comprising one or more glass-formers selected from the 
group consisting of POs, SiO, and BO; and one or more 
trace elements selected from the group consisting of Ag, Cu, 
F. Fe, Mn, Mo, Ni, Sr., and Zn in a concentration between 
about 0.05 and 10 wt % per trace element chemically dis 
solved in the biocompatible material. 
The invention is further directed to a biocompatible oint 
ment or cream for wound care management comprising an 
ointment-based carrier, glass-based particles of a biocompat 
ible material intermixed in the ointment-based carrier, 
wherein the glass-based particles comprise a glass-former 
selected from the group consisting of POs, SiO, B.O.; and 
one or more trace elements selected from the group consisting 
of Ag, Cu, F, Fe, Mn, Mo, Ni, Sr., and Zn in a concentration 
between about 0.05 and 10 wt % per trace element chemically 
dissolved in the biocompatible material. 
The invention is also directed to a biocompatible surgical 
glue for closing a wound, wherein the glue comprises an 
adhesive; glass-based particles of a biocompatible material 
intermixed in the adhesive, wherein the glass-based particles 
comprise a glass-former selected from the group consisting of 
POs, SiO, BO; and one or more trace elements selected 
from the group consisting of Ag, Cu, F, Fe, Mn, Mo, Ni, Sr. 
and Znina concentration between about 0.05 and 10 wt % per 
trace element chemically dissolved in the biocompatible 
material. 
In a further embodiment the invention is a Surgical Suture 
for closing a wound wherein the Suture comprises glass-based 
fibers of a biocompatible material comprising a glass-former 
selected from the group consisting of POs, SiO, B.O.; and 
one or more trace elements selected from the group consisting 
of Ag, Cu, F, Fe, Mn, Mo, Ni, Sr., and Zn in a concentration 
between about 0.05 and 10 wt % per trace element chemically 
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dissolved in the biocompatible material; wherein the suture 
comprises an external polymeric coating. 
In another aspect the invention is directed to a method for 
treating a wound comprising applying the dressings or oint 
ment or cream to the wound, or applying the glue to close the 
wound. 
Other objects and features of the invention are in part 
apparent and in part pointed out hereinafter. 
BRIEF DESCRIPTION OF THE FIGURES 
FIG. 1 is a photograph of a three-dimensional compressible 
body of loose glass-based fibers of the wound care dressing of 
the invention. 
FIG. 2 is a scanning electron microscope (SEM) image of 
a body of loose glass-based fibers of the invention with glass 
microspheres interspersed throughout the fibers. 
FIG. 3 is a higher magnification SEM image of a body of 
loose glass-based fibers of the dressing of the invention. 
FIGS. 4 through 14 are photographs showing the healing 
progression of wounds as described hereinbelow. 
FIG. 15 is a graphical depiction of wound area as a function 
of time as described hereinbelow. 
FIGS. 16 through 20 are photographs of histological stain 
ing (H&E) of a wound treated according to this invention. 
DESCRIPTION OF PREFERRED 
EMBODIMENTS 
In accordance with this invention, biocompatible and bio 
degradable glasses containing one or more glass-formers 
selected from the group consisting of POs, SiO, and BO 
are employed for wound care management. The glasses take 
various forms, including a flexible three-dimensional com 
pressible body of loose glass-based fibers to be held in place 
in an open wound, or to be employed as a layer applied over 
a wound. In another form, the glasses are in the form of 
particles in an ointment or cream applied to a wound. In yet 
other forms the glasses are employed as fibers formed into 
Sutures for closing a wound, or as particles in a Surgical glue 
for closing a wound. 
In a first embodiment of the invention which is a three 
dimensional compressible body of loose glass-based fibers 
such as depicted in FIG. 1, the body comprises fibers having 
a diameter between about 200 nm (0.2 Lum (microns)) and 
about 4000 nm (4 um). FIG.3 is an SEM image of such abody 
showing various fiber diameters at higher magnification. For 
example, in one embodiment the fibers have a diameter 
between about 250 nm (0.25um) and about 3000 nm (3 um), 
such as between about between about 300 nm (0.2 um) and 
about 2000 nm (2 um). The especially small diameter of these 
fibers renders them highly flexible so they form into the 
compressible body withoutbreaking. They have a texture like 
a cottonball In certain embodiments the body consists only of 
fibers meeting these dimensions, while in other embodiments 
the body includes fibers meeting these dimensional require 
ments in addition to other glass morphologies, such as fibers 
of other dimensions, microspheres, particles, ribbons, flakes 
or the like. The fibers are generally circular in cross section, 
but they may be flattish or oval or have other-shaped, non 
circular cross section, where cross section is the dimension 
transverse to the fiber's length. “Diameter as used herein 
therefore refers not only to the diameter of a circular cross 
section, but also to the largest transverse dimension of other, 
non-circular cross sections. 
The number of fibers in the assembly is not narrowly criti 














of the fibers, size of the dressing, and other factors. For 
example, in most embodiments, there are hundreds or even 
thousands offibers, such as typically at least about 10, at least 
about 50, or at least about 200 fibers. The upper limit on the 
number offibers is dictated by the size of the dressing, and for 
some embodiments is less than about 50,000, while other 
embodiments contain more. 
As shown in FIG. 2, the body may also contain, in addition 
to fine glass fibers, microspheres or beads having a diameter 
of at least about 10 um, such as between about 10 um and 
about 500 um, for example between about 20 Lum and about 
300 lum. In addition to or instead of microspheres, these 
components may be irregular or regular particles, ribbons, 
flakes, hollow spheres, or other shapes. While microspheres 
are preferred in some embodiments, the shape is not narrowly 
critical in most embodiments, and is to a large extent dictated 
more by the availability of materials than by other consider 
ations. 
The three-dimensional body of glass fibers as a whole has 
a first state which is unstressed and relaxed when it is in an 
uncompressed condition such as shown in FIG. 1. The body 
also has a second state which is stressed when it is in a 
compressed condition, which generally occurs when the body 
is shaped and applied to a wound. While the body as a whole 
is unstressed in its uncompressed condition, the individual 
fibers are to some extent stressed when they are bent. In the 
relaxed state, the body has a porosity which is at least about 
30% by volume, meaning that at least about 30 vol% of the 
body is void space not occupied by glass material. For 
example, in the relaxed state the body is between about 30 vol 
% and about 90 vol% porosity, such as between about 40 vol 
% and about 75 vol%. The body may be applied to a wound 
in an uncompressed State; or it may be compressed so that the 
porosity is between about 10 vol% and about 75 vol%, such 
as between about 10 vol% and about 50 vol%. For example, 
the body may have an uncompressed porosity of between 
about 40 vol% and 75 vol% and a compressed porosity of 
between about 10 vol% and about 30 vol%. 
The initial surface area of the compressible body varies 
depending on morphology Such as whether it is all fibers, the 
fiber dimensions, etc. Moreover, the surface area per unit 
Volume changes upon compression, upon application to a 
wound, and during biodegradation. Generally speaking, a 
compressible body according to some embodiments of the 
invention has a surface area/bulk body volume in the relaxed, 
uncompressed state of the body of between about 1 and about 
2000 cm, such as between about 50 and about 500 cm. 
In the embodiment shown in FIGS. 1 through 3 the fibers 
are randomly oriented in the body. In alternative embodi 
ments, the fibers may be woven, as may be dictated either by 
the manner in which the body is formed, or may be dictated by 
a particular application. For example, in one embodiment the 
body is in the form of a woven layer which is applied over a 
wound, similar in morphology to a woven cloth orgauze. The 
layer may be wrapped around the wound. This layer may 
constitute the entire dressing, or it may be a component of a 
multi-component dressing, Such as a multilayer dressing. 
Inasmuch as the layer may constitute the entire dressing, the 
term “layer herein is not strictly limited to a layer which is 
laid over or under another component of the dressing. 
When in the form of a layer, the body is also suitable for 
wrapping around or otherwise applying to an implant Such as 
a hip implant or a bone repair implant. This assists in fixation 
of the implant in the body. Moreover, the body of glass fibers 
in this application is suitable for delivering trace elements to 
the implant site by incorporating trace elements chemically 
dissolved in the glass material, as described hereinbelow. In 
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these applications where the glass body is a layer, it is flexible. 
Randomly oriented as well as woven fibers may be employed 
in these embodiments. 
The three-dimensional body has a length, width, and thick 
ness. In irregularly shaped embodiments such as shown in 
FIG. 1, these dimensions refer to the largest or maximum 
dimensions in each of the X, y, and Z directions. For example, 
the particular embodiment shown in FIG. 1 has a length of 
about 75 mm (3 inches as shown by the ruler), a width of about 
50 mm, and a thickness of about 5 to 25 mm. Generally 
speaking, the dimensions of the body are dictated by the size 
of the wounds for which it is applicable. The body therefore 
typically has an uncompressed length and width of at least 
about 10 mm, such as between about 10 mm and about 250 
mm, for example between about 10 and about 150 mm. 
between about 10 and about 50 mm, or between about 50 and 
200 mm. The body typically has an uncompressed thickness 
of at least about 2 mm, such as between about 2 and about 100 
mm or between about 5 and 30 mm. The body may be manu 
factured or Supplied to the end users or intermediaries in 
much larger dimensions, and cut to size by the end users or 
intermediaries. 
In those embodiments where the body is in the form of a 
layer, the thickness is generally much Smaller, for example 
less than 10 mm, such as between about 1 mm and 10 mm. In 
one embodiment it is between about 1 and about 3 mm thick. 
The layer may be in the form of a square, for example having 
a length and width between about 10 and about 300 mm, or in 
the form of a rectangle having a width between about 10 and 
about 75 mm and a length between about 50 and about 250 
mm. The layer may also be in the form of a roll having a width 
between about 10 and about 75 mm and a length greater than 
25 mm. In some preferred embodiments where the body is a 
layer, it has a length and a width which are between about 5 
and about 30 times the thickness of the body. 
In one embodiment the body is subjected to a bonding 
operation which at least lightly bonds the fibers and converts 
the body from a flexible body to a rigid body. This yields a 
rigid dressing for wound care management comprising a 
three-dimensional body of bonded glass-based fibers. 
The invention in another aspect is a biocompatible oint 
ment or cream for wound care management. This embodi 
ment employs any ointment-based or cream-based carrier 
which one skilled in the art determines is suitable for treat 
ment of the particular wound. Glass-based particles of a bio 
compatible material are intermixed in the ointment-based or 
cream-based carrier. The glass-based particles comprise a 
glass-former selected from the group consisting of POs, 
SiO, BOs. The glass-based particles further comprise one 
or more trace elements selected from the group consisting of 
Ag, Cu, F, Fe, Mn, Mo, Ni, Sr. and Zn in a concentration 
between about 0.05 and 10 wt % per trace element chemically 
dissolved in the biocompatible material. 
The invention in another embodiment is a biocompatible 
Surgical glue for closing a wound. The glue comprises an 
adhesive which one skilled in the art determines is suitable for 
treatment of the particular wound. The glue also contains 
particles of a biocompatible material intermixed in the adhe 
sive, wherein the glass-based particles comprise a glass 
former selected from the group consisting of POs, SiO, 
BO. The particles also contain one or more trace elements 
selected from the group consisting of Ag, Cu, F, Fe, Mn, Mo, 
Ni, Sr., and Zn in a concentration between about 0.05 and 10 
wt % per trace element chemically dissolved in the biocom 
patible material. The particle size for glass-based particles in 














um, such as between about 3 and about 50 um. In the context 
of the glue, ointment, and cream, the term "particles' includes 
fibers. 
Another embodiment is a Surgical Suture for closing a 
wound wherein the Suture comprises glass-based fibers of a 
biocompatible material comprising a glass-former selected 
from the group consisting of POs, SiO, B.O. The glass 
based fibers further comprise one or more trace elements 
selected from the group consisting of Ag, Cu, F, Fe, Mn, Mo, 
Ni, Sr., and Zn in a concentration between about 0.05 and 10 
wt % per trace element chemically dissolved in the biocom 
patible material. The suture preferably has an external poly 
meric coating. 
In connection with each of the foregoing embodiments, a 
trace element such as Ag, Cu, F, Fe, Mn, Mo, Ni, Sr., and Zn, 
and in some particularly preferred embodiments, Ag, Cu, Sr. 
Zn, and/or Fe, is preferably incorporated into the glass. Silver 
has infection-fighting properties. These other elements have 
an effect on endothelial cell migration which can be useful for 
blood vessel formation and have importance for tissue regen 
eration. In this way, these trace elements promote angiogen 
esis, which is a critical function in promoting tissue growth, 
Such as in wound healing. This is in distinction from promot 
ing osteoconductivity, which refers to providing bone growth 
factors to a site to promote bone growth. Angiogenesis, which 
involves increasing vascularity, i.e., vessel growth, is distinct 
from osteoconductivity. 
In those instances when the one or more trace elements are 
employed, they are incorporated into the glass in a concen 
tration of at least about 0.05 wt %, or at least about 0.1 wt %. 
In most instances, the concentration is less than 10 wt %, or 
less than 5 wt %, such as between about 0.05 and about 5 wt 
%, for example between about 0.1 and about 2.5 wt % (per 
element). Where the biocompatible glass material is borate 
based orphosphate-based, the trace element concentration is 
less than 5 wt %, and it may be higher and up to 10 wt % where 
the biocompatible material is silicate-based. The trace ele 
ments are selected from the group consisting of Ag, Cu, F, Fe, 
Mn, Mo, Ni, Sr. and Zn. In certain preferred embodiments the 
trace element is one or more selected from the group consist 
ing of Ag, Cu, Fe, Sr. and Zn. More than one of these trace 
elements can be employed in a single composition. Also, 
certain of these elements may be present in greater amounts in 
that they are not being used as trace elements in accordance 
with this invention. For example, a glass which contains 0.4 
wt % Cu and 15 wt % Sr contains Cu as a trace element in 
accordance with this invention; and it contains Sr, but not as 
a trace element in accordance with this invention. Such a 
material would indeed satisfy the requirement herein for a 
trace element from the group Ag, Cu, F, Fe, Mn, Mo, Ni, Sr. 
and Zn in a concentration between about 0.05 and 10 wt % by 
virtue of the materials Cu content, regardless of its unduali 
fying Sr content. 
Where Cu is desired, the source of Cu to the glass may be 
a copper oxide Such as CuO or CuO or other copper com 
pounds such as copper nitrate or copper Sulfate, for example. 
In one embodiment, Cu is incorporated in a concentration of 
between about 0.05 and about 5 wt % (about 0.06-6 wt % 
CuO; about 0.055-5.5 wt %CuO), such as between about 0.1 
and about 2.5 wt % (about 0.12-3 wt %CuO; about 0.11-3 wit 
% Cu.O). There are preferred embodiments employing from 
about 1 wt % to about 2 wt % Cu, as provided by between 
about 1.2 wt % and about 2.4 wt % Cu.O. 
Where Sr is desired, the source of Sr to the glass may be an 
oxide such as SrO or other Sr compounds such as SrCO, for 
example. In one embodiment, Sr is incorporated in a concen 
tration of between about 0.05 and about 5 wt % (about 0.06 to 
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5.90 wt % SrO), such as between about 0.1 and about 2.5 wt 
% (about 0.12 to 2.95 wt % SrO). There are preferred embodi 
ments employing from about 1 wt % to about 2 wt % Sr, as 
provided by between about 1.18 wt % and about 2.36 wt % 
SrO. 5 
Where Zn is desired, the source of Zn to the glass may be 
an oxide such as ZnO or other Zn compounds such as Zn 
(PO4)2-XH2O, for example. In one embodiment, Zn is incor 
porated into the glass in a concentration of between about 
0.05 and about 5 wt % (about 0.06 to 6.0 wt % ZnO), such as 10 
between about 0.1 and about 2.5 wt % (about 0.12 to 3.0 wt % 
ZnO). There are preferred embodiments employing from 
about 1 wt % to about 2 wt % Zn, as provided by between 
about 1.20 wt % and about 2.40 wt % ZnO. 
Where Fe is desired, the source of Fe to the glass may be an 15 
oxide such as FeC), Fe-O, FeO, or other Fe compounds 
such as FeSO-7H2O, for example. In one embodiment, Fe is 
incorporated into the glass in a concentration of between 
about 0.05 and about 5 wt % (about 0.06 to 6.45 wt % Fe0), 
such as between about 0.1 and about 2.5 wt % (about 0.13 to 20 
3.23 wt % FeC). There are preferred embodiments employing 
from about 1 wt % to about 2 wt % Fe, as provided by between 
about 1.29 wt % and about 2.58 wt % FeC). 
Where Ag is desired, the Source of Ag to the glass may be 
AgNO or AgPOs, for example. In one embodiment, Ag is 25 
incorporated in a concentration of between about 0.05 and 
about 5 wt %, such as between about 0.1 and about 2.5 wt %. 
The glass formers in certain embodiments of the invention 
are concentration balanced to impart the desired biodegrad 
ability. For example, in one embodiment, the concentrations 30 
of the glass formers borate, silicate, and phosphate are bal 
anced to 52.95 wt %, 0 wt %, and 4.0 wt %, respectively, with 
respect to themselves and with respect to the other compo 
nents in the material NaO, CaO, and KO. Balancing in this 
regard encompasses balancing the concentration of one glass 35 
former with other components, such as with those glasses 
which containborate and other components, but no phosphate 
or silicate. 
In many preferred embodiments, the concentrations of 
glass formers are balanced such that at least about 20 wt % of 40 
the glass biodegrades within two weeks of application to a 
wound. For example, the concentrations of glass formers are 
balanced such that at least about 20 wt % of the glass biode 
grades within two weeks of application to a Surface wound of 
a Fisher 344 rathaving an age between 9 and 11 weeks and a 45 
weight between 200 and 300 grams. In accord with this mea 
Sure, the testing is performed on rats with a standard deviation 
of 25% (relative) of the biocompatible material and a popu 
lation size of 10. In other words, when 10 of these bodies, 
ointments, creams, glues, or Sutures are applied to rat wounds, 50 
on average at least 20 wt % of the glass biodegrades within 
two weeks; and in at least 68% of rats at least 15 wt % of the 
glass biodegrades; and in at least 90% of rats at least 10 wt % 
of the glass degrades. Application for this and the following 
standards is according to the protocol described below in 55 
Example 1. Biodegrading in most instances manifests itself as 
weight loss, but can also manifest itself as another reaction of 
the material. 
Similarly, in another aspect, the concentrations of glass 
formers are balanced such that at least about 20 wt % of the 60 
trace element concentration in the bodies, ointments, creams, 
glues, or sutures is released into the host within two weeks of 
application to its mammalian host. For example, the concen 
trations of glass formers are balanced such that at least about 
20 wt % of the trace element concentration is released into the 65 
host within two weeks of application to a Fisher 344 rat 
having an age between 9 and 11 weeks and a weight between 
8 
200 and 300 grams. In accord with this measure, the testing is 
performed on rats with a standard deviation of 25% (relative) 
of the biocompatible material and a population size of 10. In 
other words, when 10 of bodies, ointments, creams, glues, or 
Sutures are applied to rat wounds, on average at least 20 wt % 
of the trace element concentration is released within two 
weeks; and in at least 68% of rats at least 15 wt % of the trace 
element concentration is released; and in at least 90% of rats 
at least 10 wt % of the trace element concentration is released. 
On the other hand, the glass in most embodiments does not 
biodegrade so quickly upon application to the host that it fails 
to provide trace elements over a long enough period to 
adequately promote angiogenesis. For example, at least 30 wit 
% of the material remains for at least two weeks and does not 
biodegrade within two weeks. That is, the concentrations of 
glass formers are balanced such that at least about 30 wt % of 
the biocompatible glass material remains in the bodies, oint 
ments, creams, glues, or Sutures for at least two weeks after 
application to a Fisher 344 rathaving an age between 9 and 11 
weeks and a weight between 200 and 300 grams. In accord 
with this measure, the testing is performed on rats with a 
standard deviation of 25% (relative) of the glass and a popu 
lation size of 10. In other words, when 10 of these bodies, 
ointments, creams, glues, or Sutures are applied to rat wounds, 
on average at least 30 wt % of the glass does not biodegrade 
within two weeks; and in at least 68% of rats at least 22.5 wt 
% of the glass does not biodegrade within two weeks; and in 
at least 90% of rats at least 15 wt % of the glass does not 
biodegrade within two weeks. 
Moreover, in these embodiments, at least 30 wt % of the 
trace element concentration remains in the bodies, ointments, 
creams, glues, or sutures for at least two weeks. That is, the 
concentrations of glass formers are balanced such that at least 
about 30 wt % of the trace element remains for at least two 
weeks after application to a Fisher 344 rat having an age 
between 9 and 11 weeks and a weight between 200 and 300 
grams. In accord with this measure, the testing is performed 
on rats with a standard deviation of 25% (relative) of the 
biocompatible body material and a population size of 10. In 
other words, when 10 of these bodies, ointments, creams, 
glues, or Sutures are applied to rat wounds, on average at least 
50 wt % of the trace element concentration remains for at least 
two weeks; and in at least 68% of rats at least 22.5 wt % of the 
trace element concentration remains in the bodies, ointments, 
creams, glues, or Sutures for at least two weeks; and in at least 
90% of rats at least 15 wt % of the trace element concentration 
remains for at least two weeks. 
In one embodiment of the invention the glass releases the 
trace element at particular rate of release of trace element, per 
gram of glass, per day in a mammalian host. The release rate 
can in effect be “dialed in” by determining the desired amount 
of trace element to be released within the host, and then 
selecting a biocompatible composition or combination of 
compositions to achieve this rate. As noted above, the glass 
formers are concentration balanced to impart the desired bio 
degradability. In a related aspect, the Surface area per unit 
Volume can be controlled to control release rate, as greater 
Surface area increases reactivity and therefore release rate. 
One skilled in the art appreciates that the rate of biodegrada 
tion of the glass is different from host to host, from glass to 
glass, from trace element to trace element, and otherwise 
depends on a number of factors. For example, a more physi 
cally active host with a faster average heart rate may encour 
age biodegradation and therefore trace element release at a 
faster rate. In one embodiment, the composition has a trace 
element release (Cu) rate of between about 0.5 and about 100 
E-7 moles of trace element, per gram of glass, per day; for 
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example, between about 1 and about 25 E-7 moles of trace 
element, per gram of glass, per day; Such as between about 1 
and about 20 E-7 moles of trace element, per gram of glass, 
per day, or between about 3 and about 12 E-7 moles of trace 
element, per gram of glass, per day. 5 
As noted above, the glass inventive bodies and other forms 
biodegrades or reacts when in contact with physiological 
fluids. However, in comparison to articles characterized as 
“water soluble' which dissolve relatively rapidly (over a 
period of, e.g., 24 hours or less) in aqueous solutions, the 
biocompatible materials of the invention are not readily 
soluble in water or aqueous liquids such as physiological 
liquids, that is, they slowly react with aqueous liquids over a 
periods of several days to weeks for the fine fibers and gen 
erally weeks to months for the microspheres and larger diam 
eter particles. As understood in the art, materials which are 
“water soluble' are subject to relatively rapid solubility; and 
materials which are “water insoluble' are either entirely 
insoluble in water, or are at least only dissolvable with diffi 
culty. Generally speaking the glass employed in the embodi 
ments of this invention are not water insoluble and are not 
water soluble under this characterization; rather, they are of 
intermediate water solubility. 
The glass material of the bodies, ointments, creams, glues, 
or sutures is biocompatible in that it is not toxic or otherwise 
harmful to its host’s living tissue. Some of the preferred 
compositions (Ca-free) of the invention are also not bioactive, 
in the sense that hydroxyapatite does not form. That is, they 
lack bioactivity, where bioactivity refers to a materials 





SiO, O to 18 
Al2O3 O to 3 
F O to 4 
transition metal elements O to 10 
cumulative. 
The concentrations of KO and MgO in certain of these 
embodiments are each from about 1 to about 25 wt.%. In most 
embodiments, the one or more of LiO, NaO, KO, and 
Rb2O is present in a cumulative concentration between about 
1 and about 50 wt %, such as between about 5 and about 20 wt 
%; and the one or more of MgO, SrO. BaO, and CaO is 
present in a cumulative concentration between about 1 and 
about 50 wt %, such as between about 5 and about 40 wt %. 
Where Cu is an optionally included trace element, this com 
position further contains 0.05 to 5; or 0.01 to 2.5 wt % Cu; as 
CuO, CuO, or other Cu compound. The transition metal 
elements are those elements where the d-band contains less 
than its maximum number of ten electrons per atom, and 
includes, among others, Co and Ni. In fact, certain of the trace 
elements used in accordance with this invention Such as Zn 
and Fe are transition metals. So in formulations where the 
trace element concentration of these trace elements is stated 
to be in aparticular range Such as between about 0.1 and about 
2.5 wt %, of course the trace element concentration is in that 
range regardless of the fact that transition elements may be 
among the trace elements, and if Zn and Fe are present in an 
amount greater than 2.5 wt %, they are not trace elements. 
A few exemplary glass materials useful in the invention are 
as follows: 
TABLE 1. 
Trace-Element-Containing Borate Biocompatible Glasses (wt % 
Glass B.O. Na-O CaO K-O MgO POs CuO SrO ZnO FeO. 
45 
ter growth of a calcium phosphate layer or convert to bone 
precursor calcium phosphate compounds which, in turn, pro 
motes bone bonding to the material. 
In one embodiment the glass employed is aborate-based 
glass material containing the following, approximately, with 50 
all percentages herein being by weight, unless stated other 
W1S 
55 
B2O3 40 to 8O 
Na2O O to 25 
Li2O O to 25 
KO O to 25 
Rb2O O to 25 
CaO O to 40 
MgO O to 25 60 
SO O to 40 
BaO O to SO 
Li2O + NaO + K2O + Rb2O O to SO 
cumulative 
MgO + SrO + BaO + CaO O to SO 
cumulative 65 
POs O to 10 
S2.95 S.99 19.98 11.99 SOO 4.OO 0.10 
52.89 S.99 19.96 11.98 4.99 3.99 0.2O 
52.79 S.98. 19.92 11.9S 4.98 3.98 0.40 
52.47 S.94 19.8O 11.88 4.95 3.96 1.00 
S1.94 S.88 19.6O 11.76 4.90 3.92 2.00 
S1.73 S.86 19.52 11.71 4.88 3.90 O.40 2.00 
S120 S.80 19.32 11.59 4.83 3.86 0.40 2.OO 100 
SO.88 5.76 19.2O 1152 4.80 3.84 040 2.OO 100 O4O 
In most embodiments the compressible body or glass par 
ticles consist only or essentially of components meeting these 
compositional requirements or other narrower descriptions 
herein. But generally speaking, for Some embodiments other 
materials not meeting these descriptions may be incorpo 
rated. 
Additional borate-based materials within this description, 
into which Ag, Cu or other stated trace element may be 
incorporated according to this invention, contain, by weight 
%, the following, keeping in mind that one or more of the 
other trace elements may be included in addition to Cu in 
analogous concentrations, or instead of Cu: 
TABLE 2 
Wt. 90 Composition of Additional Borate Glasses 
B.O. Na-O K-O LiO CaO BaO MgO POs CuO 
A 52.5 6.O 12.O 2O.O S.O 4.0 O.S 
B 70.3 10.3 19.3 O.1 
C 63.7 19.0 17.2 O.1 
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TABLE 2-continued 
Wt. 90 Composition of Additional Borate Glasses 
B.O. Na2O K-O Li2O CaO BaO MgO POs CuO 
D 490 14.6 36.0 0.4 
E 78.4 11.S 10.0 O.1 
F 69.9 1OO 100 10.O O.1 
G 78.6 11.3 1O.O O.1 
H 78.6 11.3 1O.O O.1 
I 75.9 11.0 13.0 O.1 
J 58.6 8.0 33.0 0.4 
It can therefore be appreciated that in addition to the Cu, 
and/or in addition to Ag, Cu, F, Fe, Mn, Mo, Sr. and/or Zn, the 
borate-based biocompatible glass materials include 40 to 80 
wt % BO or 50 to 80 wt % BO, or even the narrower BO 
ranges described herein, in combination with 1 to 25 wt % 
NaO, 1 to 25% KO, 1 to 40 wt % CaO, 1 to 25 wt % MgO, 
and 1 to 10 wt % POs. Or the component materials may 
contain 40 to 80 wt % BO, 1 to 25 wt % LiO, and 1 to 40 
wt % CaO. Or they may contain 40 to 80 wt % BO, 1 to 25 
wt % NaO, and 1 to 40 wt % CaO. Or they may contain 40 to 
80 wt % BO, 1 to 25 wt % NaO, and 1 to 40 wt % BaC). Or 
they may contain 40 to 80 wt % BO, 1 to 25 wt % LiO, and 
1 to 25 wt % MgO. Or they may contain 40 to 80 wt % BO, 
1 to 25 wt % LiO, and 1 to 40 wt % BaO. While the biocom 
patible materials hereinabove and hereinbelow are described 
as containing various oxides by weight%, those skilled in the 
art understand that in the final glass or glass/crystalline com 
position, the oxide compounds are dissociated, and the spe 
cific oxides, e.g., B.O., SiO, POs, etc. are not separately 
identifiable or even necessarily separately present. Nonethe 
less, it is conventional in the art to refer to the final composi 
tion as containing a given 9% of the individual oxides, so that 
is done here. So from this perspective, the compositions 
herein are on an equivalent basis. 
The biocompatible glass employed in the invention con 
taining the trace element in certain preferred versions are 
borate-based in that they contain between about 40 and about 
80 wt % BO, such as between about 50 and about 80 wt % 
B.O. Borate-based materials have several important advan 
tages for biological use Such as their ease of preparation, 
ability to be made into glass particulates, microspheres or 
fibers at relatively low temperatures without crystallization, 
and, particularly, their biocompatibility. The borate-based 
materials disclosed herein, compared to silicate-based mate 
rials, have significantly faster reaction rates, lower melting 
temperatures, resistance to crystallization, and in certain 
instances the absence of silica, which only slowly degrades in 
the body. So while certain embodiments employ up to about 
18 wt % SiO in many other preferred embodiments herein, 
the materials are silicate-free, containing less than 0.1 wt % 
silicate or even no silicate. Borate glass fibers often form 
hollow fibers upon reaction in-vivo, while silicate glasses do 
not; and they facilitate angiogenesis in-vivo. The borate mate 
rials described herein also release boron in-vivo as they react 
with the body fluids. 
There is one embodiment which has specific preference in 
certain applications and wherein the concentration of Ca (el 
emental or in CaO or other compounds) in the glass is con 
trolled to less than about 5 wt %. Certain preferred embodi 
ments strictly control the Ca concentration to less than about 
0.5 wt %, such as to less than 0.2 wt %, and even to less than 
0.1 wt %. The advantage in this embodiment to strictly con 
trolling Ca concentration is the avoidance of the formation of 














related amorphous calcium phosphate (ACP) upon exposure 
to physiological phosphorus-containing fluids. Such apatite 
compounds includehydroxyapatite Cas (PO4)(OH), fluoroa 
patite Cas (PO).F. amorphous calcium phosphate (ACP), and 
other calcium-containing compounds. Thus, in certain appli 
cations it is advantageous to avoid the formation of Ca-apatite 
compounds because they have a relatively lower radiopacity 
than do, for example, analogous Sr or Ba compounds. In 
certain situations it is advantageous to avoid Ca-apatite com 
pounds in order to form compounds which degrade more 
rapidly, or perhaps even more slowly. It can also be advanta 
geous to avoid Ca for purposes of controlling melt character 
istics, such as viscosity, melting temperature, and/or crystal 
lization tendency. The Ca-free compositions lack bioactivity, 
where bioactivity refers to a materials capacity in phospho 
rus-containing mammalian fluids to foster growth of a cal 
cium phosphate layer or convert to bone-precursor calcium 
phosphate compounds. 
The biocompatible Ca-free material employed for certain 
embodiments preferably contains between about 40 and 
about 90 wt % BO with the remainder being selected from 
alkali oxides and alkaline earth oxides, and other optional 
constituents listed below. For example, this material contains, 
by weight%: 
B2O3 40 to 80 
Na2O O to 25 
Li2O O to 25 
KO O to 25 
Rb,O O to 25 
MgO O to 25 
SO O to 40 
BaO O to 25 
LiO + NaO + K-O + Rb-O O to SO 
cumulative 
MgO + SrO + BaO O to SO 
cumulative 
POs O to 10 
SiO2 O to 18 
Al2O3 O to 3 
O to 4 
transition metal elements O to 10 
cumulative. 
In addition, the material optionally contains Cu in a concen 
tration of 0.05 to 5; or 0.01 to 2.5 wt %, as CuO, CuO, or 
other Cu compound, and/or other trace element. Certain of 
these embodiments contain low levels of Ca, as described 
above; while others are substantially Ca-free and contain 
essentially no or less than 0.1 wt % Ca. 
In one preferred embodiment, the glass contains between 
about 50 and about 80 wt % B.O.; between about 5 and about 
20 wt % alkali oxide component selected from the group 
consisting of LiO, Na2O, K2O, Rb2O, and combinations 
thereof, and between about 5 and about 40% alkaline earth 
component selected from the group consisting of MgO, SrO. 
BaO, and combinations thereof. Optional components 
include POs, SiO, Al2O, F, and transition metal elements. 
Lanthanides are specifically and strictly excluded from cer 
tain preferred embodiments. In some embodiments the bio 
compatible material consists essentially of between about 50 
and about 80 wt % B.O.; between about 5 and about 20 wt % 
alkali oxide component selected from the group consisting of 
LiO, NaO, KO, Rb O, and combinations thereof; between 
about 5 and about 40 wt % alkaline earth component selected 
from the group consisting of MgO, SrO, BaO, and combina 
tions thereof, and between about 0.05 and 5 wt % Cu, as CuO, 
Cu2O, or other Cu compound 
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Exemplary borate-based Ca-free materials, into which Cu 
may be incorporated according to this invention, contain, by 
weight%, the following; keeping in mind that one or more of 
the other trace elements may be included in addition to Cu in 
analogous concentrations, or instead of Cu: 
TABLE 3 
Wt. 90 Composition of Ca-Free Borate Glasses 
BO NaO Li2O MgO BaO CuO 
I 49.O 14.6 36.1 O.3 
II 78.7 11.1 1O.O O.2 
III 78.7 11.1 1O.O O.2 
IV 75.8 11.0 13.0 O.2 
V 58.7 8.0 33.0 O.3 
VI 4S.O 6.6 48.0 0.4 
VII 69.7 1O.O 1O.O 1O.O O.3 
In certain embodiments of the invention, the glass is 
selected to include at least two of the alkali oxides LiO, 
NaO, KO, and/or RbO in a cumulative concentration of 
between about 5 and about 25 wt %, such as between about 8 
and 20 wt %. It has been discovered to be advantageous to 
include two or more such alkali compounds in order to reduce 
the tendency for crystallization, which ultimately improves 
the workability and manufacturability of the glasses. Using 
more than one type of alkali (i.e., mixed alkali) can reduce the 
cost of a glass, modify its reaction rate with body fluids, and 
provide additional elements beneficial to tissue growth and 
regeneration. 
A further feature of certain embodiments is that the cumu 
lative concentration of the alkaline earth oxides from the 
group consisting of MgO, SrO. BaO, CaO, and combinations 
thereof is in the range of 1 to about 50 wt %, such as in the 
range of 1 to 30 wt %, or even about 8 to 25 wt %. Certain of 
these embodiments contain two or more Such alkaline earth 
oxides in a range of 1 to 45 wt % cumulatively, Such as in the 
range of 5 to 25 wt %. If SrO is present in a concentration 
which yields a Sr concentration above 10 wt %, it does not 
qualify as a trace element in accordance with this description. 
These embodiments into which Cu and/or other trace ele 
ment may be incorporated and which employ mixed alkali 
oxide contents contain BOs from about 40 to about 80 wt %. 
Certain of these embodiments consist essentially of BO 
from about 40 to about 80 wt %, mixed alkali oxides selected 
from the group consisting of LiO, Na2O, K2O, and Rb2O, 
and one of MgO, SrO, BaO, or CaO, plus the Cu or other trace 
element compound. Other embodiments consist essentially 
of BO, from about 40 to about 80 wt %, two or more alkali 
oxides selected from the group consisting of Li2O, NaO. 
KO, and RbC), and two or more alkaline earth oxides from 
the group consisting of MgO, SrO. BaO, and CaO, plus the Cu 
or other trace element compound. For example, composition 
A in Table 2 consists essentially of B.O. from about 40 to 
about 80 wt %, two or more mixed alkali oxides selected from 
the group consisting of LiO, NaO, KO, and Rb2O in a 
cumulative wt % between 5 and 25%, and two or more from 
among MgO, SrO. BaO, and CaO in a cumulative wt % 
between 8 and 25%. Other embodiments optionally include 
one or more of POs, SiO, Al-O. F. and transition metal 
elements. 
The invention includes using fibers or particles from bio 
compatible glass materials with an especially high BO com 
position, namely, from about 60 to about 82 wt %, preferably 
from about 70 to about 80 wt %. These embodiments employ 
an alkali oxide selected from the group consisting of LiO, 














from about 1 to about 50 wt %, such as from about 5 to about 
25 wt %, and even from about 8 to about 20 wt %; and even 
optionally two or more such oxides cumulatively in this 
range. They also optionally employ alkaline earth oxides 
from group consisting of MgO, SrO. BaO, CaO, and combi 
nations thereof in the range of about 1 to about 50 wt %, such 
as in the range of 1 to 30 wt %, or even about 8 to 25 wt %, and 
even two or more such oxides cumulatively in this range. 
Certain of these embodiments consist essentially of these 
components, such as compositions II, III, IV, and VII in Table 
3; while other embodiments optionally include one or more of 
POs, SiO, Al2O, F, and transition metal elements. 
In the foregoing described mixed-alkali and high-borate 
embodiments, the Ca concentration may be strictly controlled 
to less than about 5 wt %, including to less than 0.5 wt %, such 
as to less than 0.2 wt % or less than 0.1 wt % to avoid the 
formation of Ca compounds, in the manner discussed above. 
Alternatively, there are embodiments containing two or more 
alkali oxides which also contain CaO in an amount up to 
about 40 wt % to facilitate the formation of hydroxyapatite, 
other calcium phosphate compounds, or amorphous calcium 
phosphate. 
Some exemplary materials of the invention contain, 
approximately, 40 to 80 wt % BO, 0.05 to 5% CuO, and 
NaO, K2O, MgO, and POs. More specific examples contain 
or even consist essentially of 40 to 90 wt % BO, 0.1 to 5% 
CuO, 1 to 25 wt % NaO, 1 to 25 wt % K2O, 1 to 25 wt % 
MgO, and 1 to 10 wt % P.O. 
The invention in other embodiments employs glasses 
formed from a phosphate-based or silicate-based material 
which is at least partially dissolvable in mammalian bodily 
fluids, and Cu or other trace element is optionally incorpo 
rated into the biocompatible material in a concentration as 
described above. In these embodiments, POs and/or SiO, are 
glass formers and constitute about 20 to about 65 wt % P.O. 
or about 20 to about 60 wt % SiO. These materials also 
contain an alkali metal oxide component of for example, one 
or more of LiO, NaO, KO, Rb2O, Cs-O, or a mixture 
thereof in a concentration of about 8 wt % to about 55 wt %, 
such as about 10 to about 52 wt %. Many of these phosphate 
and silicate-based glasses also contain a calcium component, 
one of CaO, CaF, or mixtures thereof. For example, many of 
these glasses contain from about 5 to about 40 wt % of CaO or 
CaF, or mixtures thereof, such as about 10 to about 30 wt % 
of CaO or CaF, or mixtures thereof, or about 10 to about 15 
wt % of CaO or CaF, or mixtures thereof. Accordingly, one 
of these embodiments contains about 20 to about 65 wt % 
POs, and one or more of LiO, NaO, K2O, Rb2O, CSO, or 
a mixture thereof in a concentration of about 8 wt % to about 
55 wt %, and a calcium componentina concentration of about 
5 to about 40 wt % of CaO or CaF, and optionally Cu in a 
concentration of about 0.05 to about 5 wt %, such as between 
about 0.1 and about 2.5%. Another embodiment contains 
about 20 to about 65 wt % P.O.s, and one or more of LiO, 
NaO, K2O, Rb2O, Cs-O, or a mixture thereof in a concen 
tration of about 10 wt % to about 52 wt %, a calcium com 
ponent of CaO or CaFor mixtures thereof in a concentration 
of about 5 wt % to about 40 wt % of CaO or CaF2 or mixtures 
thereof, and Cu or other trace element in a concentration of 
about 0.05 to about 5 wt %, such as between about 0.1 and 
about 2.5%. Another embodiment contains about 20 to about 
65 wt % POs, and one or more of LiO, NaO, K2O, Rb2O, 
Cs-O, or a mixture thereof in a concentration of about 8 wt % 
to about 55 wt %, a calcium component of CaO or CaF or 
mixtures thereof in a concentration of about 10 to about 30 wt 
% of CaO or CaFor mixtures thereof, and Cu or other trace 
elementina concentration of about 0.05 to about 5 wt %, such 
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as between about 0.1 and about 2.5%. Another of these 
embodiments contains about 20 to about 60 wt % SiO, and 
one or more of LiO, NaO, KO, Rb2O, Cs-O, or a mixture 
thereof in a concentration of about 8 wt % to about 55 wt %, 
a calcium component of CaO in a concentration of about 5 to 5 
about 40 wt % of CaO or CaF2, and Cu or other trace element 
in a concentration of about 0.05 to about 5 wt %, such as 
between about 0.1 and about 2.5 wt %. Another embodiment 
contains about 20 to about 60 wt % SiO, and one or more of 
LiO, NaO, KO, Rb2O, CSO, or a mixture thereof in a 10 
concentration of about 10 wt % to about 52 wt %, a calcium 
component of CaO or CaF2 or mixtures thereof in a concen 
tration of about 5 wt % to about 40 wt % of CaO or CaFor 
mixtures thereof, and optionally Cuor other trace element in 
a concentration of about 0.05 to about 5 wt %, such as 15 
between about 0.1 and about 2.5 wt %. Another embodiment 
contains about 20 to about 60 wt % SiO, and one or more of 
LiO, NaO, KO, Rb2O, CSO, or a mixture thereof in a 
concentration of about 8 wt % to about 55 wt %, a calcium 
component of CaO or CaF2 or mixtures thereof in a concen- 20 
tration of about 10 to about 30 wt % of CaO or CaF, or 
mixtures thereof, and optionally Cuor other trace element in 
a concentration of about 0.05 to about 5 wt %, such as 
between about 0.1 and about 2.5 wt %. In certain of these 
embodiments, CaF2 is strictly avoided and the calcium com- 25 
ponent is CaO. 
Examples of silicate-based glasses containing Cu and other 
trace elements useful in this invention are as follows: 
TABLE 4 
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manufacturability of the glasses, which can be important to 
making fibers. Using more than one type of alkali (i.e., mixed 
alkali) can reduce the cost of a glass, modify its reaction rate 
with body fluids, and provide additional elements beneficial 
to tissue growth and regeneration. 
A further feature of these phosphate-based embodiments is 
that the cumulative concentration of the alkaline earth oxides 
from the group consisting of MgO, SrO. BaO, CaO, and 
combinations thereof is in the range of 1 to about 50 wt %, 
such as in the range of 1 to 30 wt %, or even about 8 to 25 wt 
%. Certain of these embodiments contain two or more such 
alkaline earth oxides in a range of 1 to 45 wt % cumulatively, 
such as in the range of 5 to 25 wt %. 
There is also an option with this invention of employing 
distinct component compositions to strategically impart cer 
tain properties. For example, the compressible body, oint 
ment, cream, glue, or Suture in Some embodiments employs 
10 to 90 wt % of components having one composition 
selected from the above, and 10 to 90 wt % of components of 
a different composition. Or even more than two such types of 
components may be employed. That is, the material may 
contain at least 10 wt % of components comprising a first 
component material within the contemplated compositions 
and at least 10 wt % of components comprising a second 
component material, wherein the first and second component 
materials have compositions distinct from each other. And it 
is contemplated that only the first component material may 
contain Cu and/or other trace element. This permits the selec 
Weight Percent Composition of Silicate-Based Biocompatible Glasses (wt % 
Glass SiO, Na2O POs CaO CuO Fe0 CaF2 BO, ZnO MnO 
44.6 24.3 5.9 24.3 1.0 
44.1 24.O 5.9 24.O 2.0 
43.7 23.8 S.8 23.8 3.0 
43.2 23.5 5.8 23:S 4.0 
42.8 23.3 5.7 233 SO 
44.O 25.O 6.O 20.0 O2 O.2 1.O 2.2 O6 O.2 
SO.O 6.O 19.0 O2 O.2 1.O 3.0 1.O O.2 
Examples of phosphate-based biocompatible glass con 
taining Cu or other trace element and useful in this invention 
are shown in Table 5. 
45 
TABLE 5 
Weight Percent Composition of Phosphate 
Based Biocompatible Glasses 
50 
Glass 
ID Na2O KO CaO MgO B.O. POs Li2O SrO CuO 
P-1 3.8 S.8 27.5 2.5 O.O 6O.O O.O. O.O. O.4 
P-2 9.2 9.3 27.5 O.O. O.O S3.5 O.O. O.O. O.S 
P-3 7.8 11.8 17.O 76 O.O SS.2, O.O. O.O. O.6 
P-4 7.8 11.8 17.0 7.6 0.0 55.2 0.0 00 0.6 55 
P-5 6.6 8.9 21.9 O.O 41 58.O O.O. O.O. O.S 
P-6 10.5 O.O 230 O.O 4.O 611 11 O.O. O.3 
P-7 8.0 3.7 1.5 O.O 1.8 78.1 O.O 6.7 O.2 
These phosphate-based formulations demonstrate situa- 60 
tions where it is advantageous to include at least two of the 
alkali oxides LiO, NaO, K2O, and/or Rb-O in a cumulative 
concentration of between about 5 and about 25 wt %, such as 
between about 8 and 20 wt %. As noted above, it has been 
discovered to be advantageous to include two or more Such 65 
alkali compounds in order to reduce the tendency for crystal 




tion of, for example, faster reacting fibers or particles in 
combination with slower reacting fibers or particles; or the 
selection of Ca-containing fibers or particles with Ca-free 
fibers or particles. One can therefore select standard compo 
sition components and combine them with non-standard 
composition components to effectively customize or dope the 
overall composition for the application presented, or for the 
host’s particular needs. Alternatively, hollow spheres con 
taining a growth factor or drug for delivery to the host can be 
incorporated with the compressible body, ointment, cream, 
glue, or Suture. 
The method of making the glass is not narrowly critical to 
the invention. By way of example, in preparing the glass, 
individual analytical reagent grade components are weighed, 
mixed thoroughly, and melted in a platinum crucible attem 
peratures ranging from 900 to 1500° C. for approximately one 
to four hours. The melt is then quenched, for example, on a 
steel or copper plate to form glass that can be ground into 
particulates of a desired size. The material of preferred com 
positions when in the form of a melt can easily beformed into 
fibers or particles. Fibers can either be pulled by hand directly 
from the melt or pulled through bushing by a rotating drum. 
The biocompatible material may be glassy, glass ceramic, 
or ceramic in nature. However the glassy state is preferred in 
this invention because, generally speaking, glassy materials 
US 8,535,710 B2 
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are stronger and more chemically homogeneous than their 
crystalline or partially crystalline counterparts of the same 
composition. In this description, the term 'glass” is used to 
include materials which are entirely glassy as well as mate 
rials which are part glassy and part crystalline. It is therefore 
preferable that the biocompatible material is substantially 
glass in that less than about 5 wt %, more preferable less than 
1 wt %, of the component material is crystalline material. The 
glass used in many embodiments of the invention, consistent 
with the foregoing description, are at least 99 wt % an amor 
phous or non-crystalline solid, for example made by fusing a 
mixture of oxides such as one or more of SiO, BO, POs 
(known as glass forming oxides) with basic oxides Such as the 
alkali and alkaline earth oxides, along with the optional one or 
more trace element compounds such as Cu compounds. In an 
alternative embodiment, the fibers or particles include glass 
ceramics fibers that contain both glassy and crystalline 
regions which in many respects function in the same manner 
as a fiber that is completely (100%) non-crystalline. The 
fibers or particles may alternatively be pre-reacted biocom 
patible glasses such as glass fibers or particles pre-reacted to 
have a thin Surface layer of hydroxyapatite. 
Example 1 
The dressing comprising a compressible body of loose 
glass-based fibers of FIG. 1 was prepared from glass of com 
position 53 wt % BO, 20 wt % CaO, 12 wt % KO, 6 wt % 
NaO, 5 wt % MgO, 4 wt % POs. As shown in FIG. 2, there 
were some residual beads (microspheres) of that are formed 
as part of the process for forming fibers. The diameter of the 
fibers ranged from of about 300 nm to about 2000 nm, as 
shown in FIG. 3. The microspheres were much larger in 
diameter and ranged from approximately 20 microns to about 
300 microns as shown in FIG. 2. 
The compressible body of FIG. 1 was used in an experi 
ment to fill a cutaneous defect in a rat. It was shaped by hand 
to forma disk about 15 mm in diameterandabout 2 mm thick. 
This cylinder was placed in a wound as shown in FIG. 4. The 
rats were Fisher 344 rats having an age between 9 and 11 
weeks and a weight between 200 and 300 grams. Prior to 
implantation, the dressings were washed twice with ethyl 
alcohol and heat sterilized at 250° C. for 2.5 hours in a small 
box furnace. For application, the back of the rat was shaved, 
sterilized with iodine, and washed with 70% ethanol. Each rat 
was anesthesized with a mixture of isofluorine and medical 
grade oxygen. After application of the dressing, 0.1 mL of 
Penicillin G Procaine was injected into each thigh of the ratto 
prevent infection. The rats were placed on a heating pad in a 
cage with fresh air during recovery. 
FIGS. 5 through 10 show a representative set of images 
showing the healing progression of a control wound (left side) 
and a wound covered with the compressible body (right side). 
The day 0 image clearly shows the wound covered with the 
dressing (white area) that fills the entire wound. The two 
wounds were monitored for about three weeks as shown by 
the images of FIGS. 5through 10, which show that the wound 
covered by the dressing healed at approximately the same rate 
as the control wound. 
FIGS. 11 through 14 show a few selected higher magnifi 
cation images to illustrate the benefits of the dressing. The 
control (no dressing) is on the left and the wound covered with 
the fiber dressing is on the right. FIG. 11 shows the open 
wounds on day 0. The wounds are moist and the exposed 
tissue appears healthy. FIG. 12 shows the wounds after four 
days, revealing that the tissue of the control wound was dried 













dressing looks like a normal scab. The scab generated by the 
dressing reacting with the underlying tissue appears to have 
formed a beneficial temporary barrier. In FIGS. 13 and 14, the 
scab can be seen peeling away from the wound as the wound 
closes. The scab on the control side in FIGS. 13 and 14 is still 
dark in color and dry. 
The area of each wound was measured periodically, and the 
average area for each control and wound covered with dress 
ing was calculated and plotted vs. time. The graph in FIG. 15 
shows there was little difference between the closure of the 
control wound and the dressing-covered wound. However, 
the dressing-covered wound had a barrier protecting it from 
its surroundings, and while possibly slowing the wound clo 
sure initially, the barrier likely helped keep out harmful 
pathogens. 
After 22 days, the animals were sacrificed, and the wounds 
and Surrounding tissue was recovered from each animal for 
histological analysis. FIG. 16 is a representative histological 
section from the wound covered with dressing. The glass 
fibers were either dissolved in the body fluids, or removed as 
the scab peeled away, as they were not visible in these photos. 
Glass microspheres that had reacted in the animal that were 
left behind from the dressing are shown in FIGS. 18, 19 and 
20. However, the microspheres seen in FIGS. 18 and 19 did 
act as an indicator of where the fibers were prior to wound 
closure. The wound dimensions were approximated by the 
presence of reacted microspheres left behind in the wound. 
The approximate original wound size (~1 cm in diameter) has 
been labeled in FIG. 16, and significant healing is evident. 
FIGS. 16 through 20 all show glass microspheres that 
reacted in-vivo to form hollow microspheres of hydroxyapa 
tite. Previous experiments have proven that the glass of the 
disclosed composition reacts to form hydroxyapatite when 
placed in an in-vivo environment. FIG. 18 is a magnified view 
of 17, and a blood vessel is seen adjacent to a reacted glass 
bead. This vessel appears to be evidence that boron, which is 
released from the glass as it reacts in-vivo, produced an angio 
genic effect in the animal and enhanced the wound healing 
process. There was also a vessel close to two of the reacted 
microspheres in FIG. 19 as indicated by the arrow, and there 
were also three vessels next to the reacted microspheres in 
FIG. 20 (circled), as indicated by the arrow. 
From the histological images present in FIGS. 16 through 
20, the tissue that was generated in the presence of the dress 
ing appears similar to the Surrounding natural tissue. After 22 
days, the dermal and epidermal layers were completely 
healed, and the subcutaneous tissue (shown in FIG. 20) had 
almost completely healed as the unhealed section of Subcu 
taneous tissue is indicated by the short horizontal arrow 
between the two vertical dotted lines in FIG. 16. FIG. 20 
shows the Subcutaneous tissue that is not completely healed 
along with some reacted glass bead. There are no visible areas 
of dead or unhealthy looking tissue, and hair along with fat 
deposits are present in the regrown tissue similar to the adja 
cent recovered tissue as shown in FIG. 17. 
In view of the above, it will be seen that the several objects 
of the invention are achieved and other advantageous results 
attained. 
When introducing elements of the present invention or the 
preferred embodiments(s) thereof, the articles “a”, “an', 
“the' and “said are intended to mean that there are one or 
more of the elements. The terms “comprising”, “including 
and “having are intended to be inclusive and mean that there 
may be additional elements other than the listed elements. 
AS Various changes could be made in the above composi 
tions and methods without departing from the scope of the 
invention, it is intended that all matter contained in the above 
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description and shown in the accompanying drawings shall be 
interpreted as illustrative and not in a limiting sense. 
The invention claimed is: 
1. A flexible dressing for wound care management com 
prising: 
a three-dimensional compressible body comprising loose 
biocompatible glass-based fibers comprising from about 
40 to 80 wt % B.O.; 
at least about 25 wt % of the fibers have a diameter between 
about 200 nm and about 4000 nm, and a length:diameter 
aspect ratio of at least about 10. 
2. The dressing of claim 1 wherein the glass-based fibers 
comprise no more than 18 wt % SiO. 
3. The dressing of claim 1 wherein the glass-based fibers 
comprise less than 0.1 wt % SiO. 
4. The dressing of claim 1 wherein the compressible body 
in its uncompressed state has a porosity of at least about 30% 
by volume. 
5. The dressing of claim 1 wherein the compressible body 
in its uncompressed state has a porosity between 40 and 75 
vol. 96. 
6. The dressing of claim 1 wherein the body further com 
prises glass components selected from the group consisting of 
beads, microspheres, regular particles, irregular particles, rib 
bons, flakes, and hollow spheres. 
7. The dressing of claim 1 wherein the compressible body 
has a surface area/bulk body volume in the relaxed, uncom 
pressed state of the body of between about 1 and about 2000 
cm', such as between about 50 and about 500 cm'. 
8. The dressing of claim 1 wherein the compressible body 
has a Surface area/bulk body Volume in the relaxed, uncom 
pressed state of the body of between about 50 and about 500 
cm'. 
9. The dressing of claim 1 wherein the glass-based fibers 
further comprise one or more trace elements selected from the 
group consisting of Ag, Cu, F, Fe, Mn, Mo, Ni, Sr. and Zn in 
a concentration between about 0.05 and 10 wt % per trace 
element chemically dissolved in the biocompatible material. 
10. The dressing of claim 9 wherein the one or more trace 
elements are homogeneously dispersed within the fibers and 
are thereby adapted to be time-released during biodegrada 
tion of said fibers. 
11. The dressing of claim 1 wherein the glass-based fibers 
comprise: 








one or more alkali oxides selected from the group consist 
ing of LiO, NaO, KO, and RbC); and 
one or more alkaline earth oxides selected from the group 
consisting of MgO, SrO. BaO, and CaO. 
12. The dressing of claim 1 wherein the glass-based fibers 
comprise: 
from about 40 to about 80 wt % B.O.; 
one or more alkali oxides selected from the group consist 
ing of Li2O, Na2O, K2O, and Rb2O in a cumulative 
concentration from 5 to 25 wt %; and 
one or more alkaline earth oxides selected from the group 
consisting of MgO, SrO. BaO, and CaO in a cumulative 
concentration from 1 to 30 wt %. 
13. The dressing of claim 1 wherein the compressible body 
comprises fibers of a first composition and fibers of a second 
composition distinct from the first composition. 
14. A flexible dressing for wound care management com 
prising: 
a three-dimensional compressible body comprising loose 
biocompatible glass-based fibers comprising from about 
40 to about 80 wt % B.O.; 
at least about 25 wt % of the fibers have a diameter between 
about 200 nm and about 4000 nm, and a length:diameter 
aspect ratio of at least about 10; 
between about 1 and about 25 wt % glass-based particles 
comprising a glass-former selected from the group con 
sisting of P-Os. SiO2, B2O, and combinations thereof, 
and having a diameter between about 10 and about 500 
um, wherein said particles are distributed among the 
fibers. 
15. The dressing of claim 14 wherein the glass-based par 
ticles are microspheres. 
16. The dressing of claim 1 wherein the fibers comprise Cu 
in a concentration between about 0.05 and 10 wt % chemi 
cally dissolved in the biocompatible material. 
17. The dressing of claim 1 wherein the compressible body 
in its uncompressed state has a thickness between about 5 mm 
and about 30 mm. 
18. The dressing of claim 1 wherein the compressible body 
is a layer. 
19. The dressing of claim 1 wherein the compressible body 
is a layer having a length and a width which are between about 
5 and about 30 times the thickness of the body. 
20. The dressing of claim 1 wherein the glass-based fibers 
further comprise POs in a concentration of 0 to 10 wt %. 
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